Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Atomi Financial Group Inc.

Atomi Financial Group Inc. boosted its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 56.4% in the third quarter, HoldingsChannel.com reports. The firm owned 34,175 shares of the company’s stock after acquiring an additional 12,329 shares during the period. Atomi Financial Group Inc.’s holdings in Takeda Pharmaceutical were worth $486,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in TAK. GAMMA Investing LLC boosted its holdings in shares of Takeda Pharmaceutical by 136.1% in the 3rd quarter. GAMMA Investing LLC now owns 6,295 shares of the company’s stock valued at $90,000 after buying an additional 3,629 shares during the period. Sanctuary Advisors LLC acquired a new position in Takeda Pharmaceutical in the second quarter valued at approximately $454,000. EP Wealth Advisors LLC bought a new position in shares of Takeda Pharmaceutical during the second quarter valued at approximately $194,000. Millennium Management LLC grew its holdings in shares of Takeda Pharmaceutical by 87.1% during the second quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock valued at $56,239,000 after purchasing an additional 2,023,707 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of Takeda Pharmaceutical by 153.7% in the 2nd quarter. AQR Capital Management LLC now owns 90,013 shares of the company’s stock worth $1,165,000 after purchasing an additional 54,539 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.1 %

NYSE:TAK opened at $14.30 on Friday. The firm has a market capitalization of $45.24 billion, a P/E ratio of 25.99, a P/E/G ratio of 0.27 and a beta of 0.54. The business has a 50 day simple moving average of $14.55 and a 200 day simple moving average of $13.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.26 and a quick ratio of 0.74. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.39.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The company had revenue of $7.75 billion during the quarter. Equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.